Literature DB >> 22684865

Causes of death of mutation carriers in Finnish Lynch syndrome families.

Kirsi Pylvänäinen1, Tuula Lehtinen, Ilmo Kellokumpu, Heikki Järvinen, Jukka-Pekka Mecklin.   

Abstract

Lynch syndrome (LS) is an autosomal dominant cancer syndrome including increased life-long risk for colorectal (CRC) and endometrial (EC) cancer, but also for cancers of other types. The risk for CRC is up to 70-80 % and for EC up to 50-60 %. Due to screening and early diagnosing the mortality related to CRC and EC seems to be low. In spite of many studies on surveillance of mutation carriers, there is no comprehensive evaluation on causes of death in LS families. The disease history and cause of death of all the deceased, tested mutation carriers and their mutation negative relatives in the Finnish LS families (N = 179) was examined utilizing hospital records and relevant national registries. Out of 1069 mutation carriers 151 had succumbed; 97 (64 %) from cancer. Out of 1146 mutation-negative family 44 members had died; 11 (25 %) of them from cancer. In 12 (7.7 %) of the deceased mutation carriers no cancer had been diagnosed. The mean age of death from cancer was 63.2 years vs. 68.8 years from non-cancer causes. Only 7.9 % of the patients with CRC had died from CRC and 5 % of those with EC, respectively. 61 % of the cancer deaths were related to extra-colonic, extra-endometrial cancers. The cumulative overall and cancer specific death rates were significantly increased in Mut+ compared to Mut- family members. Even surveillance yields decrease in the life-long risk and mortality of the most common cancers CRC and EC in LS, almost all mutation carriers will contract with cancer, and two thirds of the deceased have died from cancer. This should be taken in account in genetic counseling. Mutation carriers should be encouraged to seek help for abnormal symptoms.

Entities:  

Mesh:

Year:  2012        PMID: 22684865     DOI: 10.1007/s10689-012-9537-3

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  16 in total

1.  Compliance and Satisfaction with Long-Term Surveillance in Finnish HNPCC Families.

Authors:  Kirsi Pylvänäinen; Matti Kairaluoma; Jukka-Pekka Mecklin
Journal:  Fam Cancer       Date:  2006       Impact factor: 2.375

2.  Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later age of onset.

Authors:  Heather Hampel; Julie A Stephens; Eero Pukkala; Risto Sankila; Lauri A Aaltonen; Jukka-Pekka Mecklin; Albert de la Chapelle
Journal:  Gastroenterology       Date:  2005-08       Impact factor: 22.682

3.  Psychological consequences of predictive genetic testing for hereditary non-polyposis colorectal cancer (HNPCC): a prospective follow-up study.

Authors:  K Aktan-Collan; A Haukkala; J P Mecklin; A Uutela; H Kääriäinen
Journal:  Int J Cancer       Date:  2001-08-15       Impact factor: 7.396

4.  One to 2-year surveillance intervals reduce risk of colorectal cancer in families with Lynch syndrome.

Authors:  Hans F A Vasen; Mohamed Abdirahman; Richard Brohet; Alexandra M J Langers; Jan H Kleibeuker; Mariette van Kouwen; Jan Jacob Koornstra; Henk Boot; Annemieke Cats; Evelien Dekker; Silvia Sanduleanu; Jan-Werner Poley; James C H Hardwick; Wouter H de Vos Tot Nederveen Cappel; Andrea E van der Meulen-de Jong; T Gie Tan; Maarten A J M Jacobs; Faig Lall A Mohamed; Sijbrand Y de Boer; Paul C van de Meeberg; Marie-Louise Verhulst; Jan M Salemans; Nico van Bentem; B Dik Westerveld; Juda Vecht; Fokko M Nagengast
Journal:  Gastroenterology       Date:  2010-03-02       Impact factor: 22.682

5.  Metachronous colorectal cancer risk for mismatch repair gene mutation carriers: the advantage of more extensive colon surgery.

Authors:  Susan Parry; Aung Ko Win; Bryan Parry; Finlay A Macrae; Lyle C Gurrin; James M Church; John A Baron; Graham G Giles; Barbara A Leggett; Ingrid Winship; Lara Lipton; Graeme P Young; Joanne P Young; Caroline J Lodge; Melissa C Southey; Polly A Newcomb; Loïc Le Marchand; Robert W Haile; Noralane M Lindor; Steven Gallinger; John L Hopper; Mark A Jenkins
Journal:  Gut       Date:  2010-12-30       Impact factor: 23.059

6.  New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC.

Authors:  H F Vasen; P Watson; J P Mecklin; H T Lynch
Journal:  Gastroenterology       Date:  1999-06       Impact factor: 22.682

7.  The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome.

Authors:  Patrice Watson; Hans F A Vasen; Jukka-Pekka Mecklin; Inge Bernstein; Markku Aarnio; Heikki J Järvinen; Torben Myrhøj; Lone Sunde; Juul T Wijnen; Henry T Lynch
Journal:  Int J Cancer       Date:  2008-07-15       Impact factor: 7.396

8.  Molecular analysis of endometrial tumorigenesis: importance of complex hyperplasia regardless of atypia.

Authors:  Taina T Nieminen; Annette Gylling; Wael M Abdel-Rahman; Kyösti Nuorva; Markku Aarnio; Laura Renkonen-Sinisalo; Heikki J Järvinen; Jukka-Pekka Mecklin; Ralf Bützow; Päivi Peltomäki
Journal:  Clin Cancer Res       Date:  2009-09-01       Impact factor: 12.531

9.  Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis.

Authors:  H F Vasen; J T Wijnen; F H Menko; J H Kleibeuker; B G Taal; G Griffioen; F M Nagengast; E H Meijers-Heijboer; L Bertario; L Varesco; M L Bisgaard; J Mohr; R Fodde; P M Khan
Journal:  Gastroenterology       Date:  1996-04       Impact factor: 22.682

10.  Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial.

Authors:  John Burn; Anne-Marie Gerdes; Finlay Macrae; Jukka-Pekka Mecklin; Gabriela Moeslein; Sylviane Olschwang; Diane Eccles; D Gareth Evans; Eamonn R Maher; Lucio Bertario; Marie-Luise Bisgaard; Malcolm G Dunlop; Judy W C Ho; Shirley V Hodgson; Annika Lindblom; Jan Lubinski; Patrick J Morrison; Victoria Murday; Raj Ramesar; Lucy Side; Rodney J Scott; Huw J W Thomas; Hans F Vasen; Gail Barker; Gillian Crawford; Faye Elliott; Mohammad Movahedi; Kirsi Pylvanainen; Juul T Wijnen; Riccardo Fodde; Henry T Lynch; John C Mathers; D Timothy Bishop
Journal:  Lancet       Date:  2011-10-27       Impact factor: 79.321

View more
  11 in total

1.  Informing family members of individuals with Lynch syndrome: a guideline for clinical geneticists.

Authors:  Fred H Menko; Cora M Aalfs; Lidewij Henneman; Yrrah Stol; Miranda Wijdenes; Ellen Otten; Marleen M J Ploegmakers; Johan Legemaate; Ellen M A Smets; Guido M W R de Wert; Aad Tibben
Journal:  Fam Cancer       Date:  2013-06       Impact factor: 2.375

2.  Colorectal cancer: Update on the clinical management of Lynch syndrome.

Authors:  Henry T Lynch; Patrick M Lynch
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-04-23       Impact factor: 46.802

Review 3.  Practical issues related to uterine pathology: staging, frozen section, artifacts, and Lynch syndrome.

Authors:  Robert A Soslow
Journal:  Mod Pathol       Date:  2016-01       Impact factor: 7.842

4.  The contribution of Lynch syndrome to early onset malignancy in Ireland.

Authors:  Alice Talbot; Emily O'Donovan; Eileen Berkley; Carmel Nolan; Roisin Clarke; David Gallagher
Journal:  BMC Cancer       Date:  2021-05-26       Impact factor: 4.430

5.  Management of ovarian and endometrial cancers in women belonging to HNPCC carrier families: review of the literature and results of cancer risk assessment in Polish HNPCC families.

Authors:  Tadeusz Dębniak; Tomasz Gromowski; Rodney J Scott; Jacek Gronwald; Tomasz Huzarski; Tomasz Byrski; Grzegorz Kurzawski; Dagmara Dymerska; Bohdan Górski; Katarzyna Paszkowska-Szczur; Cezary Cybulski; Pablo Serrano-Fernandez; Jan Lubiński
Journal:  Hered Cancer Clin Pract       Date:  2015-01-16       Impact factor: 2.857

6.  Towards gene- and gender-based risk estimates in Lynch syndrome; age-specific incidences for 13 extra-colorectal cancer types.

Authors:  Christina Therkildsen; Steen Ladelund; Lars Smith-Hansen; Lars Joachim Lindberg; Mef Nilbert
Journal:  Br J Cancer       Date:  2017-10-24       Impact factor: 7.640

7.  Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database.

Authors:  Pål Møller; Toni T Seppälä; Inge Bernstein; Elke Holinski-Feder; Paulo Sala; D Gareth Evans; Annika Lindblom; Finlay Macrae; Ignacio Blanco; Rolf H Sijmons; Jacqueline Jeffries; Hans F A Vasen; John Burn; Sigve Nakken; Eivind Hovig; Einar Andreas Rødland; Kukatharmini Tharmaratnam; Wouter H de Vos Tot Nederveen Cappel; James Hill; Juul T Wijnen; Mark A Jenkins; Kate Green; Fiona Lalloo; Lone Sunde; Miriam Mints; Lucio Bertario; Marta Pineda; Matilde Navarro; Monika Morak; Laura Renkonen-Sinisalo; Mev Dominguez Valentin; Ian M Frayling; John-Paul Plazzer; Kirsi Pylvanainen; Maurizio Genuardi; Jukka-Pekka Mecklin; Gabriela Moeslein; Julian R Sampson; Gabriel Capella
Journal:  Gut       Date:  2017-07-28       Impact factor: 23.059

8.  Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts.

Authors:  Hans F A Vasen; Ignacio Blanco; Katja Aktan-Collan; Jessica P Gopie; Angel Alonso; Stefan Aretz; Inge Bernstein; Lucio Bertario; John Burn; Gabriel Capella; Chrystelle Colas; Christoph Engel; Ian M Frayling; Maurizio Genuardi; Karl Heinimann; Frederik J Hes; Shirley V Hodgson; John A Karagiannis; Fiona Lalloo; Annika Lindblom; Jukka-Pekka Mecklin; Pal Møller; Torben Myrhoj; Fokko M Nagengast; Yann Parc; Maurizio Ponz de Leon; Laura Renkonen-Sinisalo; Julian R Sampson; Astrid Stormorken; Rolf H Sijmons; Sabine Tejpar; Huw J W Thomas; Nils Rahner; Juul T Wijnen; Heikki Juhani Järvinen; Gabriela Möslein
Journal:  Gut       Date:  2013-02-13       Impact factor: 23.059

9.  Incidence of and survival after subsequent cancers in carriers of pathogenic MMR variants with previous cancer: a report from the prospective Lynch syndrome database.

Authors:  Pål Møller; Toni Seppälä; Inge Bernstein; Elke Holinski-Feder; Paola Sala; D Gareth Evans; Annika Lindblom; Finlay Macrae; Ignacio Blanco; Rolf Sijmons; Jacqueline Jeffries; Hans Vasen; John Burn; Sigve Nakken; Eivind Hovig; Einar Andreas Rødland; Kukatharmini Tharmaratnam; Wouter H de Vos Tot Nederveen Cappel; James Hill; Juul Wijnen; Mark Jenkins; Kate Green; Fiona Lalloo; Lone Sunde; Miriam Mints; Lucio Bertario; Marta Pineda; Matilde Navarro; Monika Morak; Laura Renkonen-Sinisalo; Ian M Frayling; John-Paul Plazzer; Kirsi Pylvanainen; Maurizio Genuardi; Jukka-Pekka Mecklin; Gabriela Möslein; Julian R Sampson; Gabriel Capella
Journal:  Gut       Date:  2016-06-03       Impact factor: 23.059

10.  PMS2 germline mutation c.943C>T (p.Arg315*)-induced Lynch syndrome-associated ovarian cancer.

Authors:  Xiaoqing Guo; Weimin Wu; Hao Gao; Xiaofeng Li; Qizhi He; Yong Zhu; Na Liu
Journal:  Mol Genet Genomic Med       Date:  2019-05-05       Impact factor: 2.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.